Progress in the development of matrix metalloproteinase inhibitors

被引:88
|
作者
Tu, GuoGang [1 ,2 ]
Xu, WenFang
Huang, HuiMing [2 ]
Li, ShaoHua [2 ]
机构
[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Peoples R China
[2] NanChang Univ, Coll Med, Dept Pharm, Nanchang 330006, Peoples R China
关键词
matrix metalloproteinases; MMP inhibitors; Zinc-binding groups; cancer; computer-aided drug design; angiogenesis; metastasis; proteases;
D O I
10.2174/092986708784567680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases ( MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With the failure of these inhibitors in clinical trials, more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs, a brief description of available three-dimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
引用
收藏
页码:1388 / 1395
页数:8
相关论文
共 50 条
  • [21] DEVELOPMENT OF SELECTIVE, EXOSITE BINDING MATRIX METALLOPROTEINASE (MMP) INHIBITORS
    Fields, G.
    BIOPOLYMERS, 2009, 92 (04) : 304 - 304
  • [22] Effect of matrix metalloproteinase inhibitors on rat embryo development in vitro
    Del Bigio, MR
    Seyoum, G
    CELLS TISSUES ORGANS, 1999, 165 (02) : 67 - 73
  • [23] Matrix metalloproteinase inhibitors: How can we optimize their development?
    Hidalgo, M
    Eckhardt, SG
    ANNALS OF ONCOLOGY, 2001, 12 (03) : 285 - 287
  • [24] Development of selective inhibitors and substrate of matrix metalloproteinase-12
    Devel, L
    Rogakos, V
    David, A
    Makaritis, A
    Beau, F
    Cuniasse, P
    Yiotakis, A
    Dive, V
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (16) : 11152 - 11160
  • [25] Matrix metalloproteinase inhibitors and cancer
    Lauer-Fields, JL
    Fields, GB
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (12) : 1873 - 1884
  • [26] Matrix metalloproteinase inhibitors in arthritis
    Bottomley, KM
    Johnson, WH
    Walter, DS
    JOURNAL OF ENZYME INHIBITION, 1998, 13 (02): : 79 - 101
  • [27] Matrix metalloproteinase inhibitors - A review
    Watson, SA
    Tierney, G
    BIODRUGS, 1998, 9 (04) : 325 - 335
  • [28] Matrix metalloproteinase inhibitors 1998
    Beckett, RP
    Whittaker, M
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (03) : 259 - 282
  • [29] Matrix metalloproteinase inhibitors - Preface
    Levin, JI
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (12)
  • [30] A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs
    Rossello, A
    Nuti, E
    Catalani, MP
    Carelli, P
    Orlandini, E
    Rapposelli, S
    Tuccinardi, T
    Atkinson, SJ
    Murphy, G
    Balsamo, A
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (09) : 2311 - 2314